Zhengye Biotechnology - Public Comps and Valuation Multiples

Zhengye Biotechnology Overview

About Zhengye Biotechnology

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.

Founded

2023

HQ

Employees

277

Website

jlzybio.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $186M

Last FY EBITDA $42.6M

EV

$124M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Zhengye Biotechnology Financials

See Zhengye Biotechnology valuation multiples based on analyst estimates

Zhengye Biotechnology P&L

In the most recent fiscal year, Zhengye Biotechnology reported revenue of $186M and EBITDA of $42.6M.

Zhengye Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Zhengye Biotechnology valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$186M	XXX	XXX	XXX
Gross Profit	XXX	$91.3M	XXX	XXX	XXX
Gross Margin	XXX	49%	XXX	XXX	XXX
EBITDA	XXX	$42.6M	XXX	XXX	XXX
EBITDA Margin	XXX	23%	XXX	XXX	XXX
EBIT	XXX	$17.2M	XXX	XXX	XXX
EBIT Margin	XXX	9%	XXX	XXX	XXX
Net Profit	XXX	$11.3M	XXX	XXX	XXX
Net Margin	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	$67.8M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Zhengye Biotechnology including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Zhengye Biotechnology achieved $186M in revenue and $42.6M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$186M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$91.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	49.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$42.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	22.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$17.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	9.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$11.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	6.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$67.8M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Zhengye Biotechnology

This financial data table provides comprehensive performance metrics for Zhengye Biotechnology, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Zhengye Biotechnology reported $186M in total revenue.
Fiscal year EBITDA was $42.6M.
The company maintained a gross profit margin of 49.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.9%.
Net profit margin reached 6.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Zhengye Biotechnology. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Zhengye Biotechnology Stock Performance

Zhengye Biotechnology has current market cap of $115M, and EV of $124M.

Market Cap Evolution

Zhengye Biotechnology Stock Data

As of October 2, 2025, Zhengye Biotechnology's stock price is $2.

See Zhengye Biotechnology trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$124M	$115M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Zhengye Biotechnology Valuation Multiples

Zhengye Biotechnology's trades at 0.7x EV/Revenue multiple, and 2.9x EV/EBITDA.

See valuation multiples for Zhengye Biotechnology and 15K+ public comps

Zhengye Biotechnology Financial Valuation Multiples

As of October 2, 2025, Zhengye Biotechnology has market cap of $115M and EV of $124M.

Equity research analysts estimate Zhengye Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zhengye Biotechnology's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$115M	XXX	$115M	XXX	XXX	XXX
EV (current)	$124M	XXX	$124M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	0.7x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	2.9x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	7.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	10.2x	XXX	XXX	XXX
EV/FCF	n/a	XXX	9.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Zhengye Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Zhengye Biotechnology Margins & Growth Rates

Zhengye Biotechnology's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Zhengye Biotechnology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zhengye Biotechnology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Zhengye Biotechnology and other 15K+ public comps

Zhengye Biotechnology Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	23%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	22%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	40%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial